Binimetinib is a selective MEK1/2 inhibitor used in combination with encorafenib for the treatment of BRAF-mutant melanoma. Simson Pharma's Binimetinib reference standard and impurities support stability-indicating method development for this targeted combination oncology therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Binimetinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.